The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

The growing need for cancer patient navigation and how to meet it

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The process of navigating the cancer care continuum can be extremely complex, confusing, and frustrating for patients and caregivers. To achieve better outcomes, patients need to not only be aware of their options, but also have a comprehensive understanding of them and be able to act accordingly and with purpose. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alyssa Schatz, MSW
Senior director, policy & advocacy, National Comprehensive Cancer Network
Crystal S. Denlinger, MD
Chief executive officer, National Comprehensive Cancer Network
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Thyme Care raises $97M in Series D investment

Thyme Care has announced a $97M Series D fundraise from current investors CVS Health Ventures, Foresite Capital, a16z Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, and Frist Cressey Ventures. New strategic investors include Morgan Health, a division of JPMorganChase focused on employer-sponsored healthcare, as well as Humana, Texas Oncology, and Memorial Hermann Health System, bringing Thyme Care’s total capital raised to $275M.
In Brief

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments. 
Byline
Alyssa Schatz, MSW
Senior director, policy & advocacy, National Comprehensive Cancer Network
Crystal S. Denlinger, MD
Chief executive officer, National Comprehensive Cancer Network
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account